Genetic and Epigenetic Drivers of Lung Cancer Heterogeneity and Therapy Resistance

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".

Deadline for manuscript submissions: 25 September 2026 | Viewed by 247

Editors


E-Mail Website
Guest Editor
Department of Medical Biotechnologies, Med Biotech Hub and Competence Centre, University of Siena, Strada delle Scotte 4, 53100 Siena, Italy
Interests: liquid biopsy; cfDNA exome; precision medicine; lung cancer genomics; next-generation sequencing

E-Mail Website
Guest Editor Assistant
Department of Medical Biotechnologies, Med Biotech Hub and Competence Centre, University of Siena, Strada delle Scotte 4, 53100 Siena, Italy
Interests: next-generation sequencing; circulating DNA; epigenetics; lung cancer genomics; therapeutic resistance

Special Issue Information

Dear Colleagues,

Lung cancer remains a leading cause of oncology-related mortality worldwide, presenting a formidable clinical challenge due to its profound biological heterogeneity. While the advent of precision medicine and immunotherapy has revolutionized the therapeutic landscape, the emergence of treatment resistance continues to impede long-term clinical success. This Special Issue of Genes will focus on the intricate interplay between genomic alterations and epigenetic modifications that orchestrates tumor evolution and adaptive survival.

The complexity of lung cancer is not merely a product of primary genetic mutations but is increasingly defined by a dynamic epigenetic landscape. Dysregulated DNA methylation, histone modifications, and non-coding RNA signaling contribute to cellular plasticity, enabling tumors to bypass targeted inhibitions through mechanisms such as epithelial–mesenchymal transition (EMT) or histological transformation. Decoding how these genetic and epigenetic drivers cooperate to foster a resilient tumor ecosystem is critical in identifying the next generation of predictive biomarkers and therapeutic vulnerabilities.

By showcasing original research articles and comprehensive reviews, this Special Issue will highlight cutting-edge advancements, from single-cell multi-omics to novel strategies for overcoming acquired resistance. Ultimately, integrating these molecular insights is vital in refining personalized medicine and improving patient outcomes in this evolving disease.

Dr. Maria Palmieri
Guest Editors

Dr. Viola Bianca Serio
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-small cell lung cancer (NSCLC)
  • intratumor heterogeneity
  • acquired resistance
  • DNA methylation
  • histone modifications
  • non-coding RNAs (ncRNAs)
  • epithelial–mesenchymal transition (EMT)
  • single-cell sequencing
  • liquid biopsy
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop